Pitt School of Medicine approved to conduct medical marijuana research |

Pitt School of Medicine approved to conduct medical marijuana research

Deb Erdley
Associated Press
A leaf of marijuana
Keith Srakocic/AP
The Cathedral of Learning on the University of Pittsburgh campus in Oakland

The University of Pittsburgh School of Medicine was among eight Pennsylvania medical schools certified Monday to conduct research in conjunction with Pennsylvania’s medical marijuana program.

The approval, coming just three months after Pennsylvania’s first medical marijuana dispensary opened, signals an opening of the door to research that has been restricted due to marijuana’s classification as a narcotic under federal drug laws.

While 29 states have legalized medical marijuana, research as to how and why the drug acts is limited.

“Today, medical research is so limited by the federal government that only a few doctors can even have access to medical marijuana. Pennsylvania’s premiere medical schools will be able to help shape the future of treatment for patients who are in desperate need not just here, but across the country,” Gov. Tom Wolf said in announcing the winners.

Officials at Pitt said they are pleased, but remained unsure when research will begin.

“It is important to note that Pennsylvania is the first and only state in the country to institute such a program, and we believe that the research that will be conducted by the School of Medicine in collaboration with UPMC will be of great importance in determining the safety, efficacy and effectiveness of medical cannabis products in treating specific diseases,” Pitt officials said in a statement Monday afternoon.

Most medical research is underwritten in part by the federal government or pharmaceutical companies. Under state law, this research must be financed exclusively by so-called clinical registrants—the companies that hold the grower/processor and dispensary permits for the universities.

Those permits have yet to be awarded. Pennsylvania Health Department spokesman Nate Wardle said applications for the eight clinical registrant permits will be available May 24 and must be filed no later than July 12. The law requires permit holders to demonstrate that they will be able to begin an approved research project within six months of approval.

In addition to Pitt, schools approved to participate in medical marijuana research include: Drexel University College of Medicine, Philadelphia; Lewis Katz School of Medicine at Temple University, Philadelphia; Penn State College of Medicine, Hershey; Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia; Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Lake Erie College of Osteopathic Medicine (LECOM), Erie; and the Philadelphia College of Osteopathic Medicine, Philadelphia.

Under state law patients who have one of 21 qualified medical conditions can apply for a medical marijuana card. Thus far, more than 37,000 Pennsylvanians have registered to participate in the medical marijuana program. Although research participation is voluntary, any one of them could be asked to participate.

Pennsylvania Secretary of Health Rachel Levine said Pennsylvania recently became to the first state to add opioid use disorder as an approved condition for medical marijuana treatment.

“It’s important to note that medical marijuana is not a substitute for proven treatments for opioid-use disorder. In Pennsylvania, medical marijuana will be available to patients if all other treatment fails, or if a physician recommends that it be used in conjunction with traditional therapies,” Levine said.

So far, 1,000 physicians have registered for the program with more than 600 certified as practitioners, the health department said.

Debra Erdley is a Tribune-Review staff writer. Reach her at 412-320-7996 or [email protected] or via Twitter @deberdley_trib

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.